Block for HER2/neu at Dr. Essa Lab

Block for HER2/neu at Dr. Essa Lab

The Block for HER2/neu test is a specialized molecular pathology and immunohistochemistry (IHC) evaluation performed on a formalin-fixed paraffin-embedded (FFPE) tissue block. This diagnostic test is of paramount importance in oncology, particularly for patients diagnosed with invasive breast cancer, gastric cancer, and gastroesophageal junction adenocarcinoma. Human Epidermal Growth Factor Receptor 2 (HER2/neu) is a proto-oncogene encoded by the ERBB2 gene on chromosome 17. Overexpression of the HER2 protein or amplification of the HER2/neu gene leads to uncontrolled cell proliferation, aggressive tumor behavior, and a higher rate of disease recurrence. Dr. Essa Lab, a premier diagnostic institution in Karachi, Pakistan, utilizes advanced immunohistochemical staining and molecular pathology techniques to determine the HER2/neu status of tumor tissues with high precision.

Understanding the HER2/neu status of a tumor is essential for modern oncology. It serves as both a prognostic marker (indicating the likely course of the disease) and a predictive marker (indicating how well the tumor is likely to respond to specific targeted therapies). Patients whose tumors are HER2-positive can benefit significantly from targeted therapies such as trastuzumab (Herceptin), pertuzumab, and antibody-drug conjugates like trastuzumab deruxtecan. Conversely, these expensive and potentially cardiotoxic therapies are ineffective in HER2-negative cases. Therefore, accurate testing on the paraffin block at Dr. Essa Lab is critical to ensuring that patients receive the most effective, personalized cancer treatment plan without undergoing unnecessary therapies.

Clinical Procedure: What to Expect

Patient Preparation

Because the Block for HER2/neu is performed on previously collected tissue samples (biopsy or surgical resection specimens), the patient does not need to undergo any direct physical preparation, fasting, or medication adjustments on the day of the test. However, specific documentation and sample handling guidelines must be followed:

• Tissue Block Submission: The patient or their representative must obtain the original Formalin-Fixed Paraffin-Embedded (FFPE) tissue block (often referred to as the “paraffin block” or “biopsy block”) from the pathology department of the hospital where the biopsy or surgery was performed.
• Histopathology Report: A copy of the original histopathology report corresponding to the tissue block must be submitted alongside the sample. This report provides crucial context, such as the tumor type, grade, and the specific site of the biopsy.
• Sample Integrity: Ensure the tissue block is transported in a cool, dry container, away from direct sunlight or extreme heat, to prevent the paraffin wax from melting and damaging the embedded tissue.
• Prior Treatment History: Inform the laboratory if the patient has already undergone neoadjuvant chemotherapy or hormone therapy, as this can sometimes alter receptor expression.

During the Procedure

Once the tissue block is received at Dr. Essa Lab, the analytical phase begins under the supervision of consultant pathologists:

• Sectioning: A histotechnologist uses a high-precision microtome to cut extremely thin sections (typically 3 to 5 microns thick) from the paraffin block. These sections are mounted onto specialized glass slides.
• Deparaffinization and Rehydration: The slides are treated with xylene and graded alcohols to remove the paraffin wax and rehydrate the tissue sections.
• Antigen Retrieval: To expose the HER2/neu proteins that may have been masked during formalin fixation, the slides undergo heat-induced epitope retrieval (HIER) using specific buffer solutions.
• Primary Antibody Incubation: The tissue sections are incubated with highly specific monoclonal or polyclonal antibodies directed against the intracellular or extracellular domain of the HER2/neu protein.
• Detection and Visualization: A secondary detection system labeled with an enzyme (such as horseradish peroxidase) is applied, followed by a chromogen substrate (usually diaminobenzidine, which produces a brown precipitate). This allows the pathologist to visualize the localization and intensity of HER2 protein expression under a light microscope.
• Microscopic Evaluation: A consultant pathologist examines the stained slides, evaluating the percentage of tumor cells showing membrane staining and the intensity of that staining, following standardized international guidelines (such as the ASCO/CAP guidelines).

When is a Block for HER2/neu Performed?

Invasive Breast Carcinoma Diagnosis

Every newly diagnosed case of invasive breast cancer must be tested for HER2/neu status. This is a standard clinical guideline worldwide. The test helps oncologists classify the breast cancer subtype (e.g., Luminal A, Luminal B, HER2-enriched, or Triple-Negative) and determine the overall prognosis. Knowing whether the tumor overexpresses the HER2 protein allows clinicians to formulate a highly targeted systemic therapy regimen immediately following diagnosis or surgical resection.

Gastric and Gastroesophageal Junction Adenocarcinoma

HER2/neu testing is also standard of care for patients with advanced, recurrent, or metastatic adenocarcinoma of the stomach or gastroesophageal junction. Approximately 10% to 20% of these tumors exhibit HER2 overexpression. Identifying HER2-positive status in these patients allows for the addition of trastuzumab to first-line chemotherapy regimens, which has been clinically proven to improve overall survival rates in advanced gastric cancers.

Determining Eligibility for Targeted Therapy

The primary therapeutic indication for performing a Block for HER2/neu is to evaluate whether a patient is a candidate for anti-HER2 targeted therapies. These therapies specifically bind to the HER2 receptors on cancer cells, blocking the signals that promote cell growth and survival. Because these drugs carry risks of side effects, including cardiotoxicity, the test ensures that only patients who will truly benefit from these targeted agents receive them.

Monitoring Disease Recurrence or Metastasis

If a patient experiences cancer recurrence or metastasis years after their initial diagnosis, physicians often request a HER2/neu test on a block from the metastatic site. The receptor status of a tumor can change over time or vary between the primary tumor and metastatic lesions (a phenomenon known as receptor discordance). Testing the metastatic tissue block ensures that the treatment strategy remains aligned with the tumor’s current molecular profile.

Prognostic Evaluation of Tumors

In addition to guiding therapy, HER2/neu status provides valuable prognostic information. HER2-positive breast and gastric cancers tend to grow more rapidly and have a higher propensity to spread to other organs compared to HER2-negative tumors. This information helps the clinical team determine how aggressively the cancer needs to be treated and how closely the patient should be monitored during follow-up care.

What Does a Block for HER2/neu Detect?

The Block for HER2/neu test evaluates several specific cellular and molecular parameters to determine the exact status of the receptor. The primary findings and parameters analyzed include:

• Membrane Staining Intensity: The degree of brown staining on the cell membrane of the tumor cells, categorized as faint, moderate, or strong.
• Staining Pattern: Whether the membrane staining is complete (encircling the entire cell) or incomplete (basolateral or lateral, which is common in gastric cancers).
• Percentage of Positive Tumor Cells: The proportion of invasive tumor cells showing membrane staining (e.g., greater than 10%).
• IHC Score 0 (Negative): No staining is observed, or membrane staining is incomplete and faint in less than 10% of tumor cells.
• IHC Score 1+ (Negative): Incomplete, faint membrane staining is observed in more than 10% of tumor cells.
• IHC Score 2+ (Equivocal): Weak to moderate complete membrane staining is observed in more than 10% of tumor cells. This borderline result requires reflex molecular testing.
• IHC Score 3+ (Positive): Strong, complete, circumferential membrane staining is observed in more than 10% of tumor cells.
• Gene Amplification Status: If the IHC result is equivocal (2+), molecular testing like Fluorescence In Situ Hybridization (FISH) is performed on the block to count the actual number of HER2 gene copies.
• HER2/CEP17 Ratio: In FISH testing, the ratio of the HER2 gene signal to the centromere of chromosome 17 (CEP17) signal is calculated to confirm true gene amplification.
• Average HER2 Copy Number: The average number of HER2 gene copies per tumor cell nucleus.
• Tumor Heterogeneity: Detection of distinct areas within the same tumor sample that show differing levels of HER2 expression.
• Tissue Block Adequacy: Assessment of whether the submitted block contains a sufficient number of viable, invasive tumor cells for accurate evaluation.
• Fixation Artifacts: Identification of any tissue degradation or over-fixation that might interfere with the staining accuracy.
• Internal Control Validation: Verification that normal non-cancerous ductal epithelium within the sample shows appropriate (usually negative or weak) staining, confirming the assay worked correctly.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, the processing and evaluation of a Block for HER2/neu are treated with high clinical priority due to their direct impact on cancer treatment timelines. Because immunohistochemistry requires precise tissue preparation, antigen retrieval, antibody incubation, and expert microscopic examination by a consultant pathologist, the turnaround time is typically within 3 to 5 working days from the time the block is submitted.

Once the report is finalized and signed off by the consultant pathologist, patients and their oncologists can access the results quickly. Dr. Essa Lab provides a secure online reporting portal on their official website, allowing patients to download their reports from the comfort of their homes. Additionally, reports can be accessed via the Dr. Essa Lab mobile application or collected physically from any of their major diagnostic centers across Karachi and other regions.

Block for HER2/neu Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HER2 Protein Expression (IHC)	Score 0 or Score 1+ (Negative; no significant protein overexpression)	Score 3+ (Positive; strong, complete membrane overexpression)
Equivocal Protein Expression	Not applicable	Score 2+ (Equivocal; requires reflex FISH testing to confirm gene status)
HER2/CEP17 Ratio (FISH)	Ratio less than 2.0 (No gene amplification)	Ratio equal to or greater than 2.0 (Gene amplification present)
Average HER2 Gene Copy Number	Less than 4.0 copies per cell	Greater than or equal to 6.0 copies per cell (Amplified)
Staining Pattern (Breast Cancer)	Absent or faint, incomplete membrane staining	Strong, complete, circumferential membrane staining in >10% of tumor cells
Staining Pattern (Gastric Cancer)	Absent or faint, incomplete membrane staining	Strong, complete, basolateral, or lateral membrane staining in >10% of tumor cells
Tissue Viability and Adequacy	Adequate invasive tumor cells present with optimal formalin fixation	Insufficient tumor cells, extensive necrosis, or poor fixation rendering the block uninterpretable

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Block for HER2/neu?

• Experienced Healthcare Professionals: Dr. Essa Lab boasts a team of highly qualified consultant pathologists specializing in histopathology and molecular diagnostics.
• Patient-Focused Care: The laboratory ensures a seamless sample submission process, providing clear guidance on block handling and documentation.
• Quality Diagnostic Services: Adherence to stringent internal and external quality control protocols ensures highly accurate and reproducible IHC staining.
• Professional Reporting: Reports are structured clearly, providing detailed scoring and interpretation in accordance with international ASCO/CAP guidelines.
• Modern Diagnostic Approach: The laboratory utilizes advanced automated staining platforms to minimize human error and optimize staining consistency.
• Comfortable Environment: Patients and their families are assisted with empathy and professionalism at all collection centers.
• Convenient Location: With an extensive network of branches across Karachi and Sindh, submitting tissue blocks is highly accessible.
• Commitment to Accurate Diagnosis: Dr. Essa Lab understands the critical nature of oncology diagnostics and is dedicated to delivering timely, reliable results to guide life-saving therapies.